Therefore, both semiquantitative and quantitative pharmacokinetic parameters from pre-NAC UF-MRI may serve as independent predictive markers of pCR in patients with HER2+ breast cancer [52]. This evidence concerns the gene ERBB2 and breast carcinoma.